Pathogenesis of hepatic encephalopathy: Potential future approaches

Digestive Diseases

Volumn 14, Issue , 1996, Pages 20-29

  Mullen, Kevin D ^a   Kaminsky Russ, Kristine ^a  

^a METROHEALTH MEDICAL CENTER   (United States)

Author keywords

Animal models of liver disease; Benzodiazepines; Hepatic encephalopathy; Pharmacological probes

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; DIAGNOSTIC AGENT; NEUROTOXIN;

ANIMAL; COGNITIVE DEFECT; DISEASE MODEL; FORECASTING; HEPATIC ENCEPHALOPATHY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; FORECASTING; HEPATIC ENCEPHALOPATHY; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; NEUROTOXINS; NEUROTRANSMITTER AGENTS;

EID: 2742568516     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000171580     Document Type: Article

References (37)

1. Mullen KD, McCullough AJ: Problems with animal models of chronic liver disease. Suggestions for improvement in standardization. Hepatology 1989:9:500-503.
2. Mullen KD, Birgisson S, Gacad RC, Conjcevaram H: Animal models of hepatic encephalopathy and hyperammonemia; in Fclipo V, Grisolia S (eds): Hepatic Encephalopathy. Hyperammonemia and Ammonia Toxicity. New York, Plenum Press. 1994, pp 1-10.
3. Mullen KD: Optimal animal models for the study of hepatic encephalopathy and nitrogen metabolism; in Capocaccia L, Merli M, Riggio O (eds): Advances in Hepatic Encephalopathy and Metabolic Nitrogen Exchange. Boca Raton, CRC Press, 1995, pp 279-292.
4. Bassett ML, Mullen KD, Skolnick P, Jones EA: Amelioration of hepatic encephalopathy by pharmacological antagonism of the GABA, A-benzodi-azepine receptor complex in a rabbit model of fulminant hepatic failure. Gastroenterology 1987,93:1069-1077.
5. Gammal SH, Basilc AS, Geller D, Skolnick P, Jones EA: Reversal of the behavioral and elcctrophysiolog-ical abnormalities of an animal model of hepatic encephalopathy by benzodiazepine receptor ligands. Hepatology 1990:11:371-378.
6. A-benzodiazepine receptor on hepatic encephalopathy in the rat: Comparison with uremic encephalopathy. Hepatology 1991:14:963- 968.
7. Hemeth AM, Piispök A, Steindl P, Yurdaydin C, Ferenci P: The influence of serotonin antagonists on hepatic encephalopathy in rats with thioacetamide-induced liver failure: in Capocaccia L. Merli M, Riggio O (eds): Advances in Hepatic Encephalopathy and Metabolic Nitrogen Exchange. Boca Raton, CRC Press. 1995, pp 254-258.
8. Conjeevaram HS, Nagle A, Katz A, Kaminsky-Russ K, McCullough AJ, Mullen KD: Reversal of behavioral changes in rats subjected to portacaval shunt with oral neomycin therapy. Hepatology 1994; 19:1245-1250.
9. Coy D, Zee P, Salchli F, Turek F, Blei AT: Decreased dietary protein amelioration disrupted circadian rhythms in rats with portacaval anastomosis. Gastroenterology 1992:102: A796.
10. Coy DL, Srivastava A, Gottstein J, Butlcrworth R, Blei AT: Post-operative course after portacaval anastomosis in rats is determined by the portacaval pressure gradient. Am J Physiol 1991;261:G1072-G1078.
11. Hawkins RA, Jessy J, Mans AM, DeJoseph MR: Effect of reducing brain glutamine synthesis on metabolic symptoms of hepatic encephalopathy. J Neurochem 1993:60: 1000-1006.
12. Jessy J, Mans AM, DeJoseph R, Hawkins RA: Hyperammonemia causes may of the changes found after portacaval shunting. Biochcm J 1990;272:311-317.
13. Butterworth RF, Giguric JF, Michaud CD, Lavoie J, Layrargues GP: Ammonia: Key factor in the pathogenesis of hepatic encephalopathy. Neurochem Pathol 1987:6:1-12.
14. Cohn R, Castell DO: The effect of acute hyperammonemia on the electroencephalogram. J Lab Clin Med 1966:68:195-205.
15. Eichler M, Bcssman SP: A doubleblind study of the effects of ammonium infusion on psychological functioning in cirrhotic patients. J Ncrv Mcnt Dis 1962;134:539-542.
16. Mullen KD, Basile AS: Benzodiaze-pine-receptor antagonists and hepatic encephalopathy: Where do we stand? Gastroenterology 1993:105: 937-940.
17. Bruha R, Marccek Z, Bradanova M, Votruba M: Flumazenil as a diagnostic lest for latent hepatic encephalopathy. J Hepatol 1994:20:844.
18. Gooday R, Hayes PC, Bezizi K, O’Carroll RE: Benzodiazepine receptor antagonism improves reaction time in latent hepatic encephalopathy. Eur J Gastroenterol Hepatol 1995;7:325-329.
19. Fischer JE, Baldesarini RJ: False neurotransmitters and hepatic failure. Lancet 1991;ii:75-78.
20. Ferenci P, Ebner J, Zimmerman C, Kikuta C, Roth E, Haussinger D: Overestimation of serum concentrations of y-aminobutyric acid in patients with hepatic encephalopathy by the y-aminobutyric acid-radiorc-ceptor assay. Hepatology 1988;8: 69-72.
21. Minuk GY, Winder A, Burgess ED, Sargeant EJ: Serum y-aminobutyric acid levels in patients with hepatic encephalopathy. Hepatogastroente-rologv 1985;32:171-174.
22. Ferenci P, Schafer DF, Kleinbcrger G, Hoofnaglc JH, Jones EA: Serum levels of gamma-aminobutyric acidlike activity in acute and chronic hepatocellular disease. Lancet 1983: ii:811-814.
23. Bassett ML, Mullen KD, Scholz B, Jones EA: Increased brain GABA uptake in a rabbit model of hepatic encephalopathy. Gastroenterology 1990;98:1-11.
24. Mullen KD, Szauter KM, Kamin-sky-Russ K: ‘Endogenous' benzodiazepine activity in body fluids of patients with hepatic encephalopathy. Lancet 1990:336:81-83.
25. Basilc A, Pannell L, Jeduri T, Gammal SH, Falcs HM, Jones EA, Skolnick P: Brain concentrations of benzodiazepines are elevated in an animal model of hepatic encephalopathy. Proc Natl Acad Sei USA 1990: 87:5263-5267.
26. Olasmaa M, Rothstein JP, Guidotti A, Weber RJ, Paul SM, Spector S, Zeneroli ML, Baraldi M, Costa E: Endogenous benzodiazepine receptor ligand in human and animal hepatic encephalopathy. J Neurochem 1990:55:2015-2023.
27. Pomier-Layrargues G, Gigure JF, Lavoie J, Pemcy P, Gagnon S, D’Amour M, Wells J, Butterworth RF: Flumazcnil in cirrhotic patients in hepatic coma: A randomized double-blind placebo-controlled crossover trial. Hepatology 1994:19:32- 37.
28. Butterworth RF, Wells J, Pomier-Layrargues G: Detection of benzodiazepine in hepatic encephalopathy. Hepatology 1995;21:695.
29. Widler P, Fisch HV, Schoch P, Zimmerman AM, Schlepfer JE, Reichen J: Increased benzodiazepine-like activity is neither necessary nor sufficient to explain acute hepatic encephalopathy in the thioacetamide-trcatcd rat. Hepatology 1993:18: 1459-1464.
30. Gacad R, Kaminsky-Russ K, Mullen KD: Detection of bcnzodiazc-pine-like activity in hepatic encephalopathy requires an initial lipophilic extraction procedure! Hepatology 1994;20:544-545.
31. Mullen KD, Conjeevaram HS, Kaminsky-Russ K: Studies of endogenous benzodiazepines in human hepatic encephalopathy; in Ta-bemer PV. Badawy AA (eds): Advances in Biomedical Alcohol Research. Oxford. Pergamon Press, 1993. pp 187-190.
32. Mullen KD, Kaminsky-Russ K, Tangerman A, Ferenci P: The role of benzodiazepines in the pathogenesis of hepatic encephalopathy. Hepa-tology 1993; 18:42A.
33. Mullen KD, Gacad R, Kaminsky-Russ K: Identification of substances responsible for elevated ‘benzodiazepines' in patients with hepatic encephalopathy. A complex analytical task. Hepatology 1993; 18:291 A.
34. Kreis R, Ross BD, Farrow NA, Achemian Z: Metabolic disorders of brain in chronic hepatic encephalopathy detected with H-l MR spectroscopy. Radiology 1992; 182:19- 27.
35. Brunberg JA, Kanal E, Hirsch W, Van Thiel DH: Chronic acquired hepatic failure: MR imaging of the brain at 1-5T.AJNR 1991,12:909-914.
36. Inoue E, Hori S, Narumi Y, et al: Portal systemic encephalopathy: Presence of basal ganglia lesions with high signal intensity on MR images. Radiology 1991:179:851- 855.
37. Zeneroli ML, Cioni G, Crisi G, Vez-zelli C, Ventura E: Globus pallidus alterations and brain atrophy in liver cirrhosis patients with encephalopathy. An MR imaging study. Magn Reson Imaging 1991:9:295-302.